VEGFA and neoplasm: Bevacizumab is a humanized monoclonal antibody that blocks the binding of the vascular endothelial growth factor to its receptors and results in regression of immature tumor vasculature, normalization of remaining tumor vasculature, and inhibition of further tumor angiogenesis.